A NON-INVASIVE test for iron overload disease developed by Western Australian biomedical company Resonance Health has received US Food and Drug Administration approval.
The approval allows Resonance to market its FerriScan test in the US, where an estimated four million people are afflicted with iron overload diseases such as haemochromotosis and thalassaemia.
The FDA approval follows FerriScan’s listing by the Australian regulatory authority the Therapeutic Goods Administration and European CE Mark at the end of 2004.